Managing lower urinary tract symptoms in men

Drug and Therapeutics Bulletin

Volumn 41, Issue 3, 2003, Pages 18-21

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; ENZYME INHIBITOR; FINASTERIDE; HERBACEOUS AGENT; INDORAMIN; MUSCARINIC RECEPTOR BLOCKING AGENT; PRAZOSIN; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE; TAMSULOSIN; TERAZOSIN;

ADULT; AGED; ARTICLE; BARK; BREAST TENDERNESS; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; EJACULATION DISORDER; FATIGUE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEALTH CARE COST; HUMAN; IMPAIRED BLADDER EMPTYING; IMPOTENCE; LIBIDO DISORDER; MALE; MEDICAL ASSESSMENT; NOCTURIA; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PATIENT REFERRAL; PRIMARY MEDICAL CARE; PROSTATE HYPERTROPHY; PYGEUM; RASH; RETROSPECTIVE STUDY; SABAL; SEDATION; SEXUAL DYSFUNCTION; SWEATING; SYNCOPE; TESTIS DISEASE; UNITED KINGDOM; URINARY FREQUENCY; URINARY HESITANCY; URINARY TRACT DISEASE; URINARY URGENCY; URINE FLOW RATE; URINE INCONTINENCE; URINE RETENTION; VERTIGO;

EID: 0037357876     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2003.41318     Document Type: Article

References (17)

1. Treagust J et al. Estimating a population's needs for the treatment of lower urinary tract symptoms in men: what is the extent of unmet need? J Public Health Med 2001; 23: 141-7.
2. Abrams P. New words for old: lower urinary tract symptoms for "prostatism". BMJ 1994; 308: 929-30.
3. Jacobsen SJ et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996; 155: 595-600.
4. Roberts RO et al. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol 2000; 163: 107-13.
5. Jacobsen SJ et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158: 481-7.
6. National Institute for Clinical Excellence. Referral advice. A guide to appropriate referral from general to specialist services, London: NICE, 2000.
7. Managing incontinence due to detrusor instability. DTB 2001; 39: 59-64.
8. De la Rosette JJ et al. EAU guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001; 40: 256-63.
9. Dutasteride (Avodart) for benign prostatic hyperplasia. Med Lett Drugs Ther 2002; 44: 109-10.
10. 1-adrenoreceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1-13.
11. Kassabian VS. Sexual function in patients treated for benign prostatic hyperplasia. Lancet 2003; 361: 60-2.
12. McConnell JD et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557-63.
13. Roehrborn CG et al. Efficacy and safety of dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41.
14. Abrams P. Tolterodine therapy in men with bladder outlet obstruction and symptomatic detrusor overactivity is not associated with urinary safety concerns. J Urology 2002; 167 (suppl 4): 266 [abstract no 1048].
15. Wilt T et al. Cernilton for benign prostatic hyperplasia (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software. [Last substantive update 31 March 1998].
16. Wilt T et al. Pygeum africanum for benign prostatic hyperplasia (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software. [Last substantive update 26 November 1997].
17. Wilt T et al. Serenoa repens for benign prostatic hyperplasia (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software. [Last substantive update 20 March 2002].